NCT04500548: Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H, MMR, Epcam+, POLD, POLE
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 12 Months to 25 Years (Child, Adult))
Location of Metastases: 
Additional Notes: Breast cancer patients are also eligible for Part 2 of the study if their tumors express 10 or greater mutations, also known as tumor mutation burden – high (TMB-H)
Exclusions: Patients who have had combined treatment of anti-PD-1/PD-L1 (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab) & anti-CTLA-4 inhibitors (e.g. Yervoy/Ipilimumab, tremelimumab); Patients that have received monotherapy of either are still eligible

Comments are closed.

Up ↑